Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial

作者：Jian Zhou, Li Bai, Jia Luo, Yuxian Bai, Yaozhen Pan, Xinrong Yang, Yufeng Gao, Rongshu Shi, Wenhua Zhang, Jinfang Zheng, Xiangdong Hua, Aibing Xu, Sheng Hu, Feng Zhang, Xiao‐Jun Yang, Mingxu Da, Rui Wang, Jie Ma, Weidong Jia, Dongmei Quan, Chuang Peng, Wei Yang, Guowen Yin, Yue Qi, Guifang Zhang, Xilin Du, Xiaorong Mao, Zhiqiang Meng, Shunchang Jiao, Jia Fan · 发表于：The Lancet Oncology · 年份：2025 · DOI：10.1016/s1470-2045(25)00190-1 · 被引用次数：47 · 研究领域：Lung Cancer Research Studies、Hepatocellular Carcinoma Treatment and Prognosis、Peptidase Inhibition and Analysis